DOCOMO to Exhibit at MWC Barcelona 2025, World's Largest Connectivity Exhibition
24.1.2025 06:01:00 CET | Business Wire | Press release
NTT DOCOMO, INC. announced today that it will exhibit at MWC Barcelona 2025, the world's largest connectivity exhibition, in Barcelona, Spain from March 3 to 6. DOCOMO and its parent NTT Group will showcase technologies and initiatives focused on the core themes of non-terrestrial networks (NTN) and aerospace, open radio access networks (Open RAN), and entertainment, aiming to promote international standardization and new business focused on next-generation communication technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250123714093/en/
NTT DOCOMO Booth at MWC Barcelona 2025 (Graphic: Business Wire)
DOCOMO is developing cutting-edge technologies and businesses under its brand slogan “Bridging Worlds for Wonder & Happiness.”
In the NTN and aerospace field, DOCOMO will highlight its latest initiatives under the NTT Group’s “NTT C89” space-business strategy, such as mobile-connectivity services using unmanned vehicles, or high-altitude platform stations (HAPS), that fly in the stratosphere for days or months, using relays to provide mobile connectivity in mountainous and remote areas, including at sea and in the sky.
For Open RAN, DOCOMO will showcase collaborations with global telecom operators, and also Open RAN services that leverage the strengths of various global partners, offered by OREX SAI, INC., a joint venture with NEC.
In the entertainment field, DOCOMO will display MiRZA® XR glasses by NTT QONOQ Devices, Inc., designed for diverse use cases including enterprise solutions, including a touch-and-try demonstration of the NTT XR Real Support solution for remote work enabled by XR glasses. A commercial prototype of AR glasses, which are scheduled to be released from this summer onwards, will also be on display (final specifications may vary).
Additionally, DOCOMO will showcase FEEL TECH®,an innovative technology that transforms how sensory information are shared, tailoring to the other person’s unique perception. Through a demonstration that conveys the emotions and sensations of characters alongside visuals and sound, visitors will have the opportunity to experience DOCOMO’s vision for the future of entertainment.
DOCOMO will also showcase the Virtual EXPO of Expo 2025 primarily developed by NTT QONOQ, INC. aiming for a service launch in April. This virtual site allows visitors to experience the NTT Pavilion using various devices.
DOCOMO’s booth at MWC Barcelona 2025 will be located at Stand 4E50 in Hall 4. During the exhibition, Mr. Sadayuki Abeta, Chief Open RAN Strategist at NTT DOCOMO and Chief Technology Officer at OREX SAI, will give a presentation on his company’s latest initiatives, case histories and future plans at the MWC Broadcast Stage 2025 in Hall 4 on Tuesday, March 4 from 16:15 to 16:45 (please see MWC Barcelona 2025 website to confirm final content and schedule).
About MWC Barcelona 2025
https://www.mwcbarcelona.com/
When:
March 3 to 6
08:30 to 19:00 (16:00 on last day)
Where:
Fira Gran Via
Av. Joan Carles I, 64
08908 L'Hospitalet de Llobregat
Barcelona, Spain
NTT C89 is pending trademark registration.
MiRZA® is a registered trademark of NTT QONOQ Devices, Inc. in Japan.
FEEL TECH® is a registered trademark of NTT DOCOMO, INC. in Japan
About NTT DOCOMO
NTT DOCOMO, Japan's leading mobile operator with over 89 million subscribers, is one of the global leaders in 3G, 4G and 5G mobile network technologies.
Under the slogan "Bridging Worlds for Wonder & Happiness," DOCOMO is actively collaborating with global partners to expand its business scope from mobile services to comprehensive solutions, aiming to deliver unsurpassed value and drive innovation in technology and communications, ultimately to support positive change and advancement in global society.
https://www.docomo.ne.jp/english/
View source version on businesswire.com: https://www.businesswire.com/news/home/20250123714093/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom